Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma

Published:2003-05 Issue: Volume:14 Page:i5-i10
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zelenetz A.D.,Hamlin P.,Kewalramani T.,Yahalom J.,Nimer S.,Moskowitz C.H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/suppl_1/i5/398289/mdg702.pdf

Reference25 articles.

1. A phase III comparison of CHOP versus m-BACOD versus ProMACE-CytaBOM versus MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study;Fisher;Ann Oncol,1994

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation;Philip;Blood,1991

4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP);Velasquez;Blood,1988

5. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study;Velasquez;J Clin Oncol,1994

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma;Annals of Medicine;2023-09-25

2. Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study;Cancer Medicine;2023-08-28

3. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials;Leukemia & Lymphoma;2023-08-07

4. Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2023-03

5. Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial;Journal of Managed Care & Specialty Pharmacy;2023-03